DBC-664 for adults with advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that cannot be removed by surgery and has spread or come back after treatment.
- Your tumor can be measured on scans (like CT or MRI).
- You have not had a stem cell, bone marrow, or organ transplant.
- You do not have active HIV, hepatitis B, or hepatitis C.
- You do not have an autoimmune disease that required treatment in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
This trial tests a new drug called GB268, either alone or with other treatments, for people with advanced breast cancer that has not responded to previous therapies. It aims to find out if GB268 can help shrink tumors or slow the cancer's growth.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.